# ONO-4578-08 (NCT06256328)

> A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

No report yet. It can be ordered.

- Drugs tested: ONO-4578 plus nivolumab
- Indication: chemotherapy-naïve HER2-negative unresectable advanced or recurrent gastric cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06256328
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Ono Pharmaceutical Co., Ltd.
- Conditions: Gastric Cancer
- Interventions: ONO-4578; Oxaliplatin; Capecitabine; S-1; Nivolumab; Placebo
- Enrollment: 226
- Primary outcome: Progression-free survival (PFS) (site investigator assessment)

## Some of the questions raised in the 9 indexed sources

_Automated from all 9 indexed sources (Apr 2026 – Jun 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether the effect of adding ONO-4578 differs by PD-L1 CPS, and which cutoff defines who might benefit
- Whether adding ONO-4578 to nivolumab plus chemotherapy delays progression compared with placebo
- Whether ONO-4578 improves overall survival once follow-up matures
- Whether adding ONO-4578 changes the serious adverse event burden of nivolumab plus chemotherapy

## Indexed commentary on ONO-4578-08 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 9 posts on X

## Order

Focused first edition, $750. Buy the first edition with create_order on https://mcp.erudio.com/mcp (product "first_edition", report "NCT06256328", the buyer's work email and organization), or POST https://www.erudio.com/api/orders with the same fields. It returns a Stripe checkout_url for your person to pay by card; a first edition has no agent-wallet payment. The person can also order on https://www.erudio.com/trials/ono-4578-08-nct06256328. We build the first edition within 24 hours of payment and email it to you once it passes our checks and review. If your report can't be delivered, we'll contact you and refund it in full.

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06256328", "email": "<work email>"}; the inbox owner confirms by the emailed link.
